BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 29, 2025
Home » Authors » Anette Breindl

Articles by Anette Breindl

Study: Fragile X Gene is Gate Keeper for BRCA Mutations

Sep. 26, 2012
By Anette Breindl
While studying premature ovarian aging, a team of scientists has discovered an unexpected connection between BRCA1/2 and FMR1 – genes that are both famous for reasons other than their effects on fertility.
Read More

Through Genomics, Lung Cancer Begins to Cough Up its Secrets

Sep. 24, 2012
By Anette Breindl
At the 2011 meeting of the American Society of Clinical Oncology (ASCO), outgoing president George Sledge told the audience that while drug developers were becoming smarter than "stupid cancers" – cancers defined and driven largely by a single mutation that could be attacked with targeted therapies – they needed to become smarter than "smart cancers" that are characterized by an overall high mutational load and will quickly mutate their way around any targeted therapy.
Read More

‘Final Chapter’ on XMRV? Good Luck With That One

Sep. 24, 2012
By Anette Breindl
Viruses are on the border between living and dead. So are the theories about what some of them cause. Two studies were published last week that showed no link between xenotropic murine leukemia virus-related virus (XMRV) and either chronic fatigue syndrome or prostate cancer. The scientific journals consider the matter settled with these studies. In theirs new sections, Nature and PLoS ONE wrote about “the nail in XMRV’s coffin” and “The Final Chapter on XMRV and Prostate Cancer.” Umm . . . good luck with that. Actually, the link between XMRV and prostate cancer may be laid to rest fairly...
Read More

For Seaside, Failed Trial Is No Reason to Get Irritated

Sep. 21, 2012
By Anette Breindl
There are clinical trials that miss hitting their primary endpoints by that tiny but critical amount that separates 0.051 from 0.049. And then there are clinical trials that tell you unequivocally that there is no there there – no hint of any efficacy whatsoever.
Read More

Start-up Aerial Is Ready for Takeoff; Narrow Flight Plan

Sep. 18, 2012
By Anette Breindl
With success rates that are even lower than for many other indications, therapeutics development for neurological disorders can strike fear into the brains of biotech executives.
Read More

Beta Cells Turn Younger, Not Older, During Type II Diabetes

Sep. 14, 2012
By Anette Breindl
In findings that, in the opinion of senior author Domenico Accili, turn the current approach to treating Type II diabetes on its head, researchers at Columbia University have discovered that in Type II diabetes, the insulin-producing pancreatic beta cells whose failure is at the core of the disease do not die. Quite the opposite: They become more stem cell-like.
Read More

Analysis Adds to Understanding of RV144 Vaccine Trial Results

Sep. 13, 2012
By Anette Breindl
Novel analyses of the RV144 HIV vaccine trial, also known as the Thai trial, have analyzed viral variants that were able to get past the protection the vaccine offered. Those results, published in Nature and presented at the AIDS Vaccine 2012 conference this week, add to the emerging understanding that targeting certain parts of HIV's envelope protein is likely the best path to an effective vaccine.
Read More

Visterra Makes Debut at ICAAC with Flu Antibody, Partnership

Sep. 12, 2012
By Anette Breindl
The typical way to identify a broadly neutralizing antibody is to screen B cells for one, and then look for an epitope that can induce its production.
Read More

Liver Transplantation, Molecular Motors Receive Lasker Awards

Sep. 11, 2012
By Anette Breindl
The newest advertising blitz of caffeinated-drug company Starbucks comes in the form of encouraging readers to share their favorite fall moments, with the Pumpkin Spice Latte featuring prominently, in tweets that include the hashtag #itsfallwhen.
Read More

DNA Switches Study Adds Utility to Existing GWAS Data

Sep. 10, 2012
By Anette Breindl
Last week's data deluge describing the most comprehensive map to date of regulatory elements in the human genome gave scientists new insights into how DNA that does not code for proteins functions within the genome. And that new understanding may enable them to get more information out of older genomewide association studies (GWAS).
Read More
Previous 1 2 … 233 234 235 236 237 238 239 240 241 … 399 400 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 29, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing